Sera Prognostics Taps Diagnostic Veteran as CFO to Scale Preterm Birth Test
Event summary
- Scott Gleason appointed CFO of Sera Prognostics effective August 31, 2026, bringing 25 years of healthcare diagnostics and capital markets experience.
- Gleason previously scaled OraSure's COVID-19 test to multi-hundred-million-dollar product and led strategy at Myriad Genetics.
- Outgoing CFO Austin Aerts transitions to advisory role after guiding company through successful IPO and public market transition.
- Sera focuses on commercializing PreTRM® Test for preterm birth risk prediction, addressing a $25 billion annual healthcare cost burden.
The big picture
Sera's CFO transition comes as it seeks to establish its PreTRM Test as the standard for preterm birth risk assessment, a market with significant unmet need and $25 billion in annual healthcare costs. The appointment reflects growing emphasis on commercial scaling in diagnostic companies, particularly those targeting high-cost pregnancy complications. Gleason's background in both diagnostics and capital markets suggests a focus on both operational efficiency and investor relations as Sera expands its commercial footprint.
What we're watching
- Commercial Execution
- How Gleason's diagnostic scaling experience will accelerate PreTRM Test adoption as standard of care.
- Market Penetration
- Whether Sera can convert its gold-standard evidence into broader payer coverage and reimbursement.
- Strategic Continuity
- The pace at which Aerts' institutional knowledge integrates with Gleason's new leadership approach.
Related topics